1	Title Page
2	
3	Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International
4	Standard
5	
6	Qiang Zeng, MD ^{1*} , Xue Yang, MD ^{2*} , Qi Gao, PhD ³ , Biao-yang Lin, PhD ⁴ , Yong-zhe Li, MD ⁵ ,
7	Gang Huang, $MD^{6\dagger}$ and Yang Xu, MD, Ph $D^{4,6\dagger}$
8	¹ Health Management Institute, the Second Medical Center & National Clinical Research Center
9	for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
10	² Outpatient Department, the Second Medical Center & National Clinical Research Center for
11	Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
12	³ Beijing Hotgen Biotechnology Inc., Beijing, China
13	⁴ Zhejiang University, Hangzhou, China
14	⁵ Department of Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China
15	⁶ Laboratory of Special Diagnosis & Shanghai Key Laboratory of Molecular Imaging, Shanghai
16	University of Medicine and Health Sciences, Shanghai, China
17	*These authors contributed equally to the study.
18	[†] Correspondence: Gang Huang, MD; Yang Xu, MD, PhD, <u>yxu1627@126.com</u>
19	
20	
21	
22	
23	
24	Keyword: COVID-19; vaccine; non-responders; WHO; international standard; CD4 cells;
25	CD8 cells; B cells; BAU/mL; IU/mL
26	

27 ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with more than 485 millions infected. Questions about non-responders to SARS-CoV-2 vaccines remain unaddressed. Here, we report data from people after administering the complete dose of SARS-CoV-2 vaccines using the World Health Organization International Standard for anti-SARS-CoV-2 immunoglobulin. Our study showed that immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike immunoglobulin G levels were significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the ≥ 60 yr group. A titer of anti-SARS-CoV-2 spike immunoglobulin G is blew 50 BAU/mL to be considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster vaccination may be recommended for non-responders to reduce the disease severity and mortality.

58 INTRODCTION

59

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic,
infecting more than 485 million people and killing more than 6 million.¹ Since December 2020
the World Health Organization (WHO) recommends vaccination against COVID-19, nine types
of coronavirus disease 2019 (COVID-19) vaccines have been included in the emergency use
list.²

65

Vaccination against COVID-19 is especially important in reducing severe illness and mortality.
According to the data of the Centers for Disease Control and Prevention (CDC) in 2016-2017,
the mortality rate caused by influenza virus was 0.13%.³

69

In order to bring the COVID-19 pandemic under control as soon as possible and ensure that the 70 mortality rate of COVID-19 is close to that caused by influenza virus, the prevention and 71 treatment of children as well as elderly and immunocompromised people has emerged as a top 72 priority at present.⁴⁻⁸ Sun et al. first reported that hospitalization and severe outcomes were 73 similar in unvaccinated healthy individuals and immunocompromised patients who received full 74 SARS-CoV-2 vaccination in the United States, suggesting that COVID-19 breakthrough 75 infection after SARS-CoV-2 vaccination is associated with immune dysfunction. Hospitalization 76 77 and severe outcomes were 21.1% and 1.9%, respectively, in unvaccinated healthy individuals, and 20.7% and 2.1%, respectively, in patients with immune dysfunction after 14 days following 78 79 full vaccination, indicating that an immune barrier is not well established in immunocompromised patients after full vaccination and post-vaccination testing is necessary to 80 81 identify immunocompromised individuals without specific immunity so they can be given additional prophylaxis after full vaccination.⁸ This study suggests that post-vaccination testing 82 will help reduce mortality, showing the importance and urgency of post-vaccination assessments 83 using an international standard. 84

85

To date, more than 5 billion people have been vaccinated against COVID-19.⁹ In clinical trials associated with COVID-19 vaccines, the effective COVID-19 vaccination reportedly elicits specific antibody responses. An effective humoral immune response is defined as $a \ge 4$ -fold

increase in antibody titers from baseline within 1–3 months of the vaccination procedure and is
considered gold standard for assessing antibody protection in vaccinated recipients.¹⁰⁻¹² In
contrast, a non-responder is an individual who demonstrates no effective humoral immune
response despite the completion of the suggested vaccination procedure.¹³⁻¹⁴

93 During the promotion of vaccination, several factors affecting the response to the COVID-19 94 vaccines were taken into consideration, especially the reduced response to the COVID-19 95 vaccine in children, elderly people, and immunocompromised population. However, despite the 96 completion of COVID-19 vaccination in the population as per the recommendations by WHO, 97 the outcomes concerning the protective levels of antibody concentration and factors determining 98 the identification of non-responders still remain inconclusive.¹⁵⁻²⁵

99

To this end, in December 2020, WHO issued an international standard (IS) for the quantification 100 of anti-SARS-CoV-2 immunoglobulin for post-vaccination testing.²⁶⁻²⁷ This standard provides a 101 102 unified benchmark for effective antibody protective concentrations after vaccination. In this clinical study, we analyzed 627 people that volunteered to participate in COVID-19 vaccination 103 and subsequent assessment of antibody titers. After two doses of vaccination, the antibody titer 104 was evidently increased by ≥ 4 times from baseline as the gold standard. Furthermore, the data 105 106 using the WHO IS was comprehensively analyzed to provide insights for improving the efficacy of vaccines, help in reduction of breakthrough infections after vaccines, and ultimately to reduce 107 108 the disease severity and mortality.

109

110 **RESULTS**

111 Immune characteristics of 627 cases prior to vaccination

There were 42.4% (266/627) individuals aged ≥ 60 yr and 50.9% (319/627) male enrolled in the study (Table 1). In the 18–59 yr group, the medians [interquartile ranges (IQRs)] of ALC, CD4 cell count, CD8 cell count, B cell count, and NK cell count were 1,476 (1,168–1,875), 851 (677– 1,151), 490 (357–632), 256 (179–367), and 193 (141–287)/mm³, respectively. On the contrary, in the ≥ 60 yr group, the respective medians (IQRs) were 1,281 (1,023–1,520), 747 (562–955), 418 (288–544), 204 (138–303), and 234 (162–355)/mm³ (Table 1). In fact, the number of naïve lymphocytes, CD4 cells, CD8 cells, and B cells were significantly reduced in the elderly population than that in the 18–59 yr population (P < 0.001). Hence, these naïve immune cells wane significantly, while the NK cell counts increase significantly in the elderly people (Table 1, Fig. 1A).

122

123 Anti-spike IgG levels in the 627 cases after complete vaccination

We analyzed the anti-spike immunoglobulin (Ig)G levels after complete vaccination of the 627 124 cases (Table 1). Post-vaccination testing was done at intervals of 14 to 90 days after the second 125 vaccine dose. The anti-spike IgG seropositive rates were 99.7% in the 18-59 yr population and 126 98.9% in the ≥ 60 yr population based on the cutoff (Table 1). However, the quantitative level of 127 the anti-spike IgG was significantly lower in the ≥ 60 yr group (median 307.2, IQRs 118.2–417.3) 128 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs 355.7–479.2 BAU/mL) (Table 1, 129 Fig. 1B). The reference ranges (2.5–97.5 percentile) were 88.6–576.2 BAU/mL in the 18–59 yr 130 group and 27.7–491.0 BAU/mL in the ≥ 60 yr group at 14–90 days after complete vaccination 131 (Table 2). 132

133

134 Characteristics of seroconversion after the complete dose

Thereafter, we evaluated the vaccine-induced responses, based on the post-second-dose and presecond-dose titers, using the 4-fold increase parameter (fold-index <4 or \geq 4) (Table 2). Remarkably, there were 7.5% non-responders (fold-index < 4) among the 18–59 yr group and 11.7% in the \geq 60 yr group (Table 2, Fig. 1C), indicating that the positive rate of anti-spike IgG cannot represent the seroconversion rate. Therefore, the anti-spike IgG positivity or seroprevalence might not be a suitable predictor of seroconversion (fold–index \geq 4).

141

142 In the 18–59 yr group, the median (IQRs) levels of anti-spike IgG and the reference ranges were 115.8 (88.6–167.8) and 18.3–266.3 BAU/mL with fold-index < 4, respectively and 420.8 (369.9– 143 480.6) and 200.7–576.5 BAU/mL with fold-index \geq 4, respectively (P < 0.0001). In contrast, in 144 the ≥ 60 yr group, the median (IQRs) levels of anti-spike IgG and the reference ranges were 63.9 145 (35.1–106.9) and 5.4–317.8 BAU/mL with fold-index < 4, respectively and 346.0 (160.4–424.7) 146 and 46.6–491.1 BAU/mL with fold-index \geq 4, respectively (P < 0.0001). The reference ranges 147 (1–99 percentile) for responders (fold–index \geq 4) were 43.9–592.0 BAU/mL in combination of 148 the 18–59 yr group and the ≥ 60 yr group at 14–90 days after complete vaccination (Figure 1C). 149

We further observed that the seroconversion rate was significantly related to the proportion of 151 152 certain naïve immune cells (Table 2). Particularly, the lymphocyte count was significantly different (P < 0.0001) between the fold-index <4 or ≥4 groups. For instance, in the 18–59 yr 153 group, the lymphocyte count was $1,130/\text{mm}^3$ [95% CI (1,007–1,252)/mm³] in the <4 group and 154 $1.578/\text{mm}^3$ [95% CI (1.524–1.633)/mm³] in the >4 group. On the contrary, in the >60 yr group, 155 the lymphocyte count was $1,015/\text{mm}^3$ [95% CI (888–1,143)/mm³] in the <4 group and 156 1,344/mm³ [95% CI 1,291–1,397)/mm³] in the \geq 4 group. Similarly, the CD4 cell counts were 157 significantly different (P < 0.0001) between the individuals with fold-index <4 and >4. For 158 instance, in the 18–59 vr population, the CD4 cell count was 631/mm³ [95% CI (555–708)/mm³] 159 versus 942/mm³ [95% CI (905–979)/mm³] in the <4 and \geq 4 groups, respectively, while in the 160 ≥60 yr age group, it was 563/mm³ [95% CI (494–631)/mm³] versus 818/mm³ [95% CI (777– 161 858/mm³] in the <4 and \geq 4 groups, respectively. With respect to the B cell count, there was a 162 significant difference (P < 0.0001) between the individuals with fold-index < 4 and > 4. For 163 example, in the 18–59 age group, the B cell count was 119/mm³ [95% CI (72–166)/mm³ versus 164 $306/\text{mm}^3$ [95% CI (289–323)/mm³] in the <4 and ≥4 groups, respectively, whereas in the ≥60 yr 165 age group, it was 74/mm³ [95% CI (60–88) /mm³] versus 248/mm³ [95% CI (231–266)/mm³] in 166 the <4 and \geq 4 groups, respectively. Regarding the CD8 cell count, a significant difference was 167 noted only between the individuals with <4 and >4 fold-indices in the 18–59 yr age group 168 $[414/\text{mm}^3 (95\% \text{ CI } 349-479/\text{mm}^3) \text{ versus } 532/\text{mm}^3 (95\% \text{ CI } 508-557/\text{mm}^3), P = 0.0081].$ 169 However, the CD8 cell count in the ≥ 60 yr group and NK cell count in both the age groups did 170 not portray any significant differences. 171

172

173 **DISCUSSION**

174

To the best of our knowledge, this is the first clinical study to report non-responders after administering the complete dose of inactivated SARS-CoV-2 vaccines using WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (Ig). Whether there is a humoral immune response following COVID-19 vaccination is a marker of population immunity.²⁸⁻³⁰ Typically, effective humoral immune response is defined as $a \ge 4$ -fold rise in antibody titers from baseline within 1-3 months of the vaccination schedule. The use of anti-SARS-CoV-2 assays with the WHO IS can facilitate the comparison of the strength of the humoral immune response between individuals, making the data more accurate and providing reliable data for the COVID-19 vaccine booster. Therefore, adequate clinical trials are necessary regarding the assessment of immune characteristics of individuals prior to vaccine booster shot, such that the mortality in the pandemic may be quickly reduced.

186

We used an anti-SARS-CoV-2 spike quantitative IgG kit (COVID-SeroKlir Kantaro SARS-CoV-187 2 IgG Ab Kit) approved by the Food and Drug Administration (FDA) under Emergency Use 188 Authorization (EUA) with the WHO IS. This kit has been extensively evaluated in many clinical 189 studies, including neutralizing antibodies after SARS-CoV-2 infection, immunological memory 190 to SARS-CoV-2, convalescent plasma treatment of severe COVID-19, and antibody responses to 191 mRNA vaccines in healthy people and patients.³⁰⁻³⁵ After complete two dose vaccination, the 192 reference ranges (1–99 percentile) for all responders (fold–index \geq 4) were 43.9–592.0 BAU/mL. 193 A preliminary cutoff of 50 BAU/mL was set based on percentiles of all responders and 194 convenience of manufacturing standard controls. The final cutoff value will be determined by 195 196 future clinical trials.

197

The WHO IS has demonstrated to be enabled to comparison between different types of vaccines. Zitt et al. reported that the median titers of non-seroconversion and seroconversion were 635.5 and 1,565.0 BAU/mL after two doses of mRNA vaccination in hemodialysis patients at 67.6 \pm 14.8 years, respectively;³⁶ whereas we reported that the median titers of non-seroconversion and seroconversion were 63.9 and 346.0 BAU/mL after giving two doses of inactivated SARS-CoV-2 vaccines at 67 \pm 6 years, respectively, indicating that the mRNA vaccines is more potent than the inactivated SARS-CoV-2 vaccines.³⁷

205

The benefits of post-vaccination serologic testing outweigh the potential risks. Zitt et al. reported there were median titer of 1,440 BAU/mL in documented hepatitis B virus (HBV) vaccine responders (anti-HBs antibody \geq 10 mIU/mL) and median titer of 308.5 BAU/mL in nonresponders after two doses of mRNA vaccination (*P* = 0.035), suggesting that post-vaccination testing might predict the general immune competence.³⁶ All anti-SARS-CoV-2 spike IgGpositive patients recovered from the infection respond well to the vaccine, which indirectly proves this phenomenon.²⁹⁻³⁰ If this theory turns out to be correct, then it is possible that SARS-CoV-2 vaccine responders have a strong ability to produce antibodies against variants through asymptomatic infections. This may support the Government-issued "immunity passports" to demonstrate an individual's immune ability according to the WHO IS (\geq 50 BAU/mL) after recovered from COVID-19 or SARS-CoV-2 vaccination.

217

The most significant benefit of post-vaccination serologic testing is to save patient lives. Chukwu 218 et al. reported clinical findings in a group of kidney transplant recipients vaccinated with 2 doses 219 of vaccines (72% of BNT162b2, 28% of AZD1222). There were 22 breakthrough infections and 220 3 deaths after vaccination, including 77% (17/22) infections and 13.6% (3/22) deaths in the 221 seronegative group and only 23% (5/22) infections and 0% (0/22) deaths in the seropositive 222 group.³⁸ However, this study did not use the WHO IS to get a cutoff for the responder. Therefore, 223 there may be some non-responders (fold-index <4) in the seropositive group according to our 224 225 study.

226

For SARS-CoV-2 vaccine non-responders, one benefit from post-vaccination serologic testing to the patient is to get a booster shot as soon as possible.³⁹⁻⁴⁰ For persistent non-responders to SARS-CoV-2 vaccination, anti-SARS-CoV-2 antibody injections could save these lives in the seronegative group after the vaccination.⁴¹⁻⁴³

231

Another good example for post-vaccination serologic testing is the HBV vaccine. After the first 232 233 hepatitis B vaccine was approved in the United States in 1981 and the recombinant hepatitis B vaccine developed by Maurice Hilleman was approved by the FDA in 1986, it took scientists 234 235 more than 20 years to realize that the vaccine did not provide good protection for the elderly and certain immunocompromised populations and put them at risk of breakthrough infections after 236 vaccination.⁴⁴⁻⁴⁵ Szmuness et al. have first reported that 7.4% of immunized individuals fail to 237 elicit detectable specific antibodies after two doses of hepatitis B vaccine, suggesting that there 238 are non-responders in the population in 1982.⁴⁶ Roome et al. have found in 1993 that 11.9% of 239 individuals with hepatitis B vaccine were no or inadequate levels of antibody, suggesting that 240 post-vaccination testing should be done at intervals of 30 to 90 days after the last vaccine dose.⁴⁷ 241 Many subsequent studies have shown that the elderly and immunocompromised populations are 242

associated with reduced vaccine responses to hepatitis B vaccination.⁴⁵⁻⁴⁷ The CDC has
recommended post-vaccination serologic testing using the WHO IS for immunocompromised
individuals following HBV vaccination.⁴⁵ For persistent non-responders (anti-HBs antibody <10
mIU/mL, the WHO IS 07/164) to HBV vaccination, anti-HBV Ig injections are recommended if
exposed to HBV.⁴⁵

248

Furthermore, the lower immune cell count may form the major risk factor for non-responders 249 after administration of full SARS-CoV-2 vaccine in our study. Van Oekelen et al. have 250 demonstrated that 32.3% (10/31) of multiple myeloma patients with severe lymphopenia 251 (<500/mm³) remained negative for SARS-CoV-2 spike IgG after two doses of mRNA vaccines 252 (OR 2.89, 95% CI 1.10–7.20, P = 0.018).⁴⁸ Similarly, two studies reported that 63.7–77.3% of 253 patients who had a history of anti-CD20 therapy for B cell depletion remained negative for 254 SARS-CoV-2 IgG after receiving mRNA vaccines, suggesting that B cells are required for 255 humoral immunity following COVID-19 vaccines.⁴⁹⁻⁵⁰ Hence, further clinical trials must be 256 performed to finalize effective booster shots for immunocompromised people after administering 257 the complete dose in the general population.⁵¹⁻⁵⁵ 258

259

260 According to this study, the anti-spike IgG seropositivities were 99.7% and 98.9% in the 18–59 yr and ≥ 60 yr groups, respectively. Additionally, certain naïve immune cells, such as CD4 cells, 261 262 CD8 cells, and B cells exhibited significant waning in the elderly people, suggesting that the non-seroconversion rates were higher in individuals with lower immune cell counts. Incidentally, 263 264 the anti-spike IgG seroprevalence or positivity was inconsistent with seroconversion rates observed in our study, thereby suggesting that anti-spike IgG positivity might not be a suitable 265 266 predictor for the seroconversion rates. Our data showed that 7.5-11.7% of non-responders existed in the population, even some non-responders with anti-spike IgG positivity, supporting the 267 CDC's concern that some non-responders are positive for anti-spike IgG after vaccination.⁵⁶ An 268 FDA EUA quantitative assay with the WHO IS (20/136) may help to address this issue.²⁶⁻²⁷ 269

270

There are several potential strategies that can be employed to reduce the COVID-19 mortality rate below 0.13 % of that caused by influenza virus. These include the following measures: (1) Increase the vaccination rate of the population;² (2) Develop vaccines against emerging and

potential variants;⁵⁷⁻⁶² (3) Administer booster vaccines for non-responders;⁶³⁻⁶⁵ (4) Assessment of
humoral immune response of children, the elderly, and immunocompromised persons within 1–3
months after 4th dose;^{45, 65-70} and (5) Incorporate additional protective measures for individuals
with persistent (4th or 5th dose) negative humoral immune response after booster vaccination,
such as injection of anti-SARS-CoV-2 immunoglobulins, antiviral drug treatment, usage of N95
masks in endemic areas, etc.^{41-43, 71-74}

280

281 CONCLUSIONS

Immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike IgG levels were significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the ≥ 60 yr group. A titer of anti-SARS-CoV-2 spike IgG is blew 50 BAU/mL to be considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster vaccination may be recommended for non-responders to reduce the disease severity and mortality.

288

289 ACKNOWLEDGMENTS

290

Limitations: Study limitations include small sample size, data was only sourced from a single
 center, and lack of RBD/spike-specific cellular immune assessments.

293

294 Funding: This work was supported by the project of "Antibody Immunity Evaluation after

SARS-CoV-2 Vaccination in General Population" (Z211100002521024) from Beijing Science
and Technology Commission.

297

Author Contributions: Drs Zeng and Xu had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Zeng and Yang served as co-first authors and contributed equally to the work. Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Zeng and Xu. Critical revision of the manuscript for important intellectual content: Zeng, Huang and Xu. Statistical analysis: Zeng, Huang and Xu. Obtained funding: Zeng and Gao. Administrative, technical, or material support: Zeng, Yang, Lin, Xu. Supervision: Zeng and Xu.

305	
306	Institutional Review Board Statement: The study was approved by the institutional ethics
307	committee (No. S2021-481-01).
308	
309	Informed Consent Statement: All study participants provided their informed written consent.
310	
311	Competing interests: None.
312	
313	Data and materials availability: All data are available in the manuscript or the supplementary
314	materials.
315	
316	
317	
318	
319	
320	
321	
322	
323	
324	
325	
326	
327	
328	
329	
330	
331	
332	
333 334	
334 335	
222	

336 **REFERENCES**


- 1. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int/
- 338 2. World Health Organization. COVID-19 advice for the public: Getting vaccinated.
 339 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice
- 340 3. Centers for Disease Control and Prevention. Burden estimates for the 2016-2017 influenza season.
 341 https://www.cdc.gov/flu/about/burden/2016-2017.html
- 4. Marks KJ, Whitaker M, Anglin O et al. Hospitalizations of children and adolescents with laboratory-confirmed
- 343 COVID-19 COVID-NET, 14 States, July 2021–January 2022. Morbidity and Mortality Weekly Report (MMWR).
- **344** 2022;71(7):271–278.
- 5. Tenforde MW, Self WH, Adams K et al. Association between mRNA vaccination and COVID-19 hospitalization
 and disease severity. JAMA. 2021;326, 2043–2054. doi: 10.1001/jama.2021.19499.
- 347 6. Zeng Q, Li YZ, Dong SY et al. Dynamic SARS-CoV-2-specific immunity in critically ill patients with
 348 hypertension. Front Immunol. 2020;11, 596684. doi: 10.3389/fimmu.2020.596684.
- 7. Lipsitch M, Krammer F, Regev-Yochay G et al. SARS-CoV-2 breakthrough infections in vaccinated individuals:
 measurement, causes and impact. Nat. Rev. Immunol. 2022;22:57–65. doi: 10.1038/s41577-021-00662-4.
- 8. Sun J, Zheng Q, Madhira V et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern. Med. 2022;182:153–162. doi:
- **352** infection after SARS-CoV-2 vaccination in the US. JAMA Intern. Med. 2022;182:153–162. doi: **353** 10.1001/iamainternmed.2021.7024.
- 354 9. Johns Hopkins University & Medicine. Understanding vaccination progress.
 355 https://coronavirus.jhu.edu/vaccines/international
- 356 10. Xia SL, Zhang YT, Wang YX et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-
- CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis 2022; 22: 196–208. DOI:https://doi.org/10.1016/S1473-3099(21)00462-X.
- 359 11. Xia S, Duan K, Zhang Y et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and
 360 immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020 Sep 8;324(10):951-960.
 361 doi: 10.1001/jama.2020.15543.
- 362 12. Long QX, Liu BZ, Deng HJ et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med.
 363 2020;26(6):845-848. doi: 10.1038/s41591-020-0897-1.
- 364 13. Weissman JY, Tsuchiyose MM, Tong MJ et al. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA. 1988;260(12):1734-1738.
- 366 14. Simon D, Tascilar K, Fagni F et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with
 367 immune-mediated inflammatory disease. Ann Rheum Dis. 2021;annrheumdis-2021-221554. doi:
 368 10.1136/annrheumdis-2021-221554.
- 369 15. Atmar RL, Lyke KE, Deming ME et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J
 370 Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414.
- 371 16. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J
 372 Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
- 17. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med.
- 374 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 18. Benenson S, Oster Y, Cohen MJ et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care
 workers. N Engl J Med. 2021 May 6;384(18):1775-1777. doi: 10.1056/NEJMc2101951.
- 19. Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination
- 378 setting. N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.
- 20. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J
 Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
- 21. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med.
 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 383 22. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in
 384 solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
- 385 23. Goldshtein I, Nevo D, Steinberg DM et al. Association between BNT162b2 vaccination and incidence of SARS-
- 386 CoV-2 infection in pregnant women. JAMA. 2021;326(8):728-735. doi: 10.1001/jama.2021.11035.
- 387 24. Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based
- heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
- 389 Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8.
- 390 25. Al Kaabi N, Zhang Y, Xia S et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19

- 391 infection in adults: A randomized clinical trial. JAMA. 2021;326(1):35-45. doi: 10.1001/jama.2021.8565.
- 26. Kristiansen PA, Page M, Bernasconi V et al. WHO International Standard for anti-SARS-CoV-2 392 393 immunoglobulin. Lancet 2021;397:1347-1348. doi:10.1016/S0140-6736(21)00527-4.
- 394 27. Knezevic I, Mattiuzzo G, Page M et al. WHO International Standard for evaluation of the antibody response to
- 395 COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 2022;3: e235-40. doi:
- 396 10.1016/S2666-5247(21)00266-4.
- 397 28. Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection 398 from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8.
- 399
- 29. Saadat S, Rikhtegaran Tehrani Z et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325(14):1467-1469. doi: 400 401 10.1001/jama.2021.3341.
- 402 30. Krammer F, Srivastava K, Alshammary H et al. Antibody responses in seropositive persons after a single dose of 403 SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372-1374. doi: 10.1056/NEJMc2101667.
- 404 31. Wajnberg A, Amanat F, Firpo A et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. 405 Science. 2020;370:1227-1230. doi: 10.1126/science.abd7728.
- 406 32. Amanat F, Thapa M, Lei T et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to 407 NTD, RBD, and S2. Cell. 2021;184(15):3936-3948.e10. doi: 10.1016/j.cell.2021.06.005.
- 408 33. Liu STH, Lin HM, Baine I et al. Convalescent plasma treatment of severe COVID-19: a propensity score-409 matched control study. Nat. Med. 2020;26:1708-1713. doi: 10.1038/s41591-020-1088-9.
- 410 34. Amanat F, Stadlbauer D, Strohmeier S et al. A serological assay to detect SARS-CoV-2 seroconversion in 411 humans. Nat. Med. 2020;26: 1033-1036. doi: 10.1038/s41591-020-0913-5.
- 35. Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after 412 413 infection. Science. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063.
- 414 36. Zitt E, Davidovic T, Schimpf J et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021;12:704773. doi: 10.3389/fimmu.2021.704773. 415
- 416 37. Sauré D, O'Ryan M, Torres JP et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2
- COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56-63. doi: 417 418 10.1016/S1473-3099(21)00479-5.
- 419 38. Chukwu CA, Mahmood K, Elmakki S et al. Evaluating the antibody response to SARS-COV-2 vaccination
- 420 amongst kidney transplant recipients at a single nephrology centre. PLoS One. 2022;17(3):e0265130. doi: 421 10.1371/journal.pone.0265130.
- 39. Accorsi EK, Britton A, Fleming-Dutra KE et al. Association between 3 Doses of mRNA COVID-19 vaccine and 422
- 423 symptomatic infectioncaused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639-651. doi: 424 10.1001/jama.2022.0470.
- 425 40. Rottenberg Y, Grinshpun A, Ben-Dov IZ et al. Assessment of response to a third dose of the SARS-CoV-2
- 426 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. JAMA Oncol. 2022;8(2):300-427 301. doi: 10.1001/jamaoncol.2021.6764.
- 428 41. Weinreich DM, Sivapalasingam S, Norton T et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients 429 with Covid-19. N Engl J Med. 2021;384(3):238-251. doi: 10.1056/NEJMoa2035002.
- 430 42. O'Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent 431 Covid-19. N Engl J Med. 2021;385(13):1184-1195. doi: 10.1056/NEJMoa2109682.
- 432 43. Weinreich DM, Sivapalasingam S, Norton T et al. REGEN-COV antibody combination and outcomes in 433 outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. doi: 10.1056/NEJMoa2108163.
- 434 44. Tulchinsky TH. Maurice Hilleman: Creator of vaccines that changed the world. Case Studies in Public Health. 435 2018;443-470. doi:10.1016/B978-0-12-804571-8.00003-2.
- 436 45. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of 437 hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization
- 438 Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. quiz CE1-4.
- 439 46. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy
- 440 and subtype cross-protection. N Engl J Med. 1982;307(24):1481-6. doi: 10.1056/NEJM198212093072403.
- 441 47. Roome AJ, Walsh SJ, Cartter ML et al. Hepatitis B vaccine responsiveness in Connecticut public safety 442 personnel. JAMA. 1993;270(24):2931-4.
- 48. Van Oekelen O, Gleason CR, Agte S et al. Highly variable SARS-CoV-2 spike antibody responses to two doses 443
- 444 of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028-1030 (2021). doi: 445 10.1016/j.ccell.2021.06.014.
- 446 49. Ollila TA, Lu S, Masel R et al. Antibody response to COVID-19 vaccination in adults with hematologic


- 447 malignant disease. JAMA Oncol. 2021;7:1714–1716. doi: 10.1001/jamaoncol.2021.4381.
- 448 50. Greenberger LM, Saltzman LA, Senefeld JW et al. Antibody response to SARS-CoV-2 vaccines in patients with
 449 hematologic malignancies. Cancer Cell. 2021;39:1031–1033. doi: 10.1016/j.ccell.2021.07.012.
- 450 51. Massarweh A, Eliakim-Raz N, Stemmer A et al. Evaluation of seropositivity following BNT162b2 messenger
- 451 RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133-1140.
- 452 doi: 10.1001/jamaoncol.2021.2155.
- 453 52. Obeid M, Suffiotti M, Pellaton C et al. Humoral responses against variants of concern by COVID-19 mRNA
- 454 vaccines in immunocompromised patients. JAMA Oncol. 2022; e220446. doi: 10.1001/jamaoncol.2022.0446.
- 455 53. Maneikis K, Šablauskas K, Ringelevičiūtė U et al. Immunogenicity of the BNT162b2 COVID-19 mRNA
 456 vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national
 457 prospective cohort study. Lancet Haematol. 2021;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1.
- 458 54. Kamar N, Abravanel F, Marion O et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant
 459 recipients. N Engl J Med. 2021;385(7):661-662. doi: 10.1056/NEJMc2108861.
- 460 55. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
- 462 56. Centers for Disease Control and Prevention. Using antibody tests for COVID-19.
 463 https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests.html
- 464 57. Lustig Y, Nemet I, Kliker L et al. Neutralizing response against variants after SARS-CoV-2 infection and one
 465 dose of BNT162b2. N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036.
- 466 58. Garcia-Beltran WF, St Denis KJ, Hoelzemer A et al. mRNA-based COVID-19 vaccine boosters induce
 467 neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457-466.e4. doi:
 468 10.1016/j.cell.2021.12.033.
- 469 59. Collie S, Champion J, Moultrie H et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South
 470 Africa. N Engl J Med. 2022;386(5):494-496. doi: 10.1056/NEJMc2119270.
- 471 60. Andrews N, Stowe J, Kirsebom F et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.
 472 N Engl J Med. 2022:NEJMoa2119451. doi: 10.1056/NEJMoa2119451.
- 472 N Engr J Med. 2022. NEJM0a2119451. doi: 10.1050/NEJM0a2119451.
 473 61. Madhi SA, Kwatra G, Myers JE et al. Population immunity and Covid-19 severity with Omicron variant in
- 474 South Africa. N Engl J Med. 2022 Feb 23:NEJMoa2119658. doi: 10.1056/NEJMoa2119658. Online ahead of print
- 474 South Africa. N Engl J Med. 2022 Feb 25. NEJMoa2119058. doi: 10.1050/NEJMoa2119058. Online anead of print
 475 62. Lopez Bernal J, Andrews N, Gower C et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta)
- 476 variant. N Engl J Med. 2021;385(7):585-594. doi: 10.1056/NEJMoa2108891.
- 477 63. Hall VG, Ferreira VH, Ku T et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant
 478 recipients. N Engl J Med. 2021;385(13):1244-1246. doi: 10.1056/NEJMc2111462.
- 479 64. Benotmane I, Gautier G, Perrin P et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2
- vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-5.
 doi: 10.1001/jama.2021.12339.
- 482 65. Kamar N, Abravanel F, Marion O et al. Assessment of 4 Doses of SARS-CoV-2 messenger RNA-based vaccine
- 483 in recipients of a solid organ transplant. JAMA Netw Open. 2021;4(11):e2136030. doi:
 484 10.1001/jamanetworkopen.2021.36030.
- 485 66. Sfeir MM, Snayd M. Serologic testing for hepatitis B. JAMA. 2021 Dec 21;326(23):2423-2424. doi:
 486 10.1001/jama.2021.19803.
- 487 67. Zheng H, Zhang GM, Chan PL et al. Compliance among infants exposed to hepatitis B virus in a post-vaccination serological testing program in four provinces in China. Infect Dis Poverty. 2019 ;8(1):57. doi: 10.1186/s40249-019-0568-y.
- 68. Trevisan A, Frasson C, De Nuzzo D et al. Significance of anti-HB levels below 10 IU/L after vaccination against
 hepatitis B in infancy or adolescence: an update in relation to sex. Hum Vaccin Immunother. 2020;16(2):460-464.
- 492 doi: 10.1080/21645515.2019.1656483.
- 493 69. Le MH, Yeo YH, So S et al. Prevalence of hepatitis B vaccination coverage and serologic evidence of immunity
 494 among US-born children and adolescents from 1999 to 2016. JAMA Netw Open. 2020;3(11):e2022388. doi:
- 495 10.1001/jamanetworkopen.2020.22388.
- 496 70. Wood RC, MacDonald KL, White KE et al. Risk factors for lack of detectable antibody following hepatitis B
 497 vaccination of Minnesota health care workers. JAMA. 1993;270(24):2935-9.
- 498 71. Wen W, Chen C, Tang J et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir,
- 499 fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022 Dec;54(1):516-523. doi:
 500 10.1080/07853890.2022.2034936.
- 501 72. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.
- 502 BMJ. 2021;375:n2713. doi: 10.1136/bmj.n2713.

- 73. Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA.
- 2022 ;327(7):617-618. doi: 10.1001/jama.2022.0335. 74. Baker MA, Rhee C, Tucker R et al. Rapid control of hospital-based SARS-CoV-2 omicron clusters through daily
- sal use of N95 respirators. Clin Infect Dis. 2022 Feb 7:ciac113. doi: 10.1093/cid/ciac113.

506	testing and univer
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
521	
522	
523	
524	
525	
526	
527	
528	
529	
530	
531	
532	
533	
534	
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	







- 554

Fig. 1. Immune characteristics of 627 individuals. (A) Naïve cellular immune parameters of the 627 cases who received physical examinations. These naïve immune cells wane significantly, while the natural killer (NK) cell counts increase significantly in the elderly people. ALC = absolute lymphocyte count. (B) The anti-spike IgG levels after complete vaccination of the 627 cases. The quantitative level of the anti-spike IgG was significantly lower in the ≥ 60 yr group (median 307.2, IQRs 118.2–417.3 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs 355.7–479.2 BAU/mL, P < 0.001. Mean and standard error of the mean (SEM) were shown. (C) The vaccine-induced responses using the 4-fold increase after complete vaccination of the 627 cases. There were 7.5% non-responders (fold-index < 4) among the 18–59 yr group and 11.7% in the ≥ 60 yr group. The reference ranges (1–99 percentile) for responders (fold-index \geq 4) were 43.9–592.0 BAU/mL in combination of the 18–59 yr group and the \geq 60 yr group. A cutoff line at fold-index 4 was showed. (D) In the responder group (fold-index \geq 4), intervals for 1– 99 percentile were 131.8–592.3 BAU/mL in the 18–59 yr group, and 29.7–500.9 BAU/mL in the ≥ 60 yr group, respectively. Mean and standard error of the mean (SEM) were shown.

572 Tables

574 Table 1. Immune characteristics of individuals before and after vaccination

Characteristics	18–59 yr group	≥60 yr group	P value
Total number of cases	361	266	
Sex (%)			
Male	183 (50.7)	136 (51.1)	
Female	178 (49.3)	130 (48.9)	
Mean age (SD) in yr	45 (9)	67 (6)	
Naïve immune cells, median (IQRs)			
Lymphocytes (/mm ³)	1,476 (1,168–1,875)	1,281 (1,023-1,520)	< 0.001
CD4 cells (/mm ³)	(1,100 1,073) 851 (677–1,151)	(1,025 1,020) 747 (562–955)	< 0.001
CD8 cells (/mm ³)	490	418	< 0.001
B cells (/mm ³)	(357–632) 256 (170–267)	(288–544) 204 (128–202)	< 0.001
Natural killer cells (/mm ³)	(179–367) 193 (141–287)	(138–303) 234 (162–355)	< 0.001
Anti-spike IgG			
Seropositivity % (no.)	99.7 (360/361)	98.9 (263/266)	
Median (IQRs) (BAU/mL)	416.8 (355.7–479.2)	307.2 (118.2–417.3)	< 0.001

602 Table 2. Characteristics of seroconversion after the complete dose of inactivated SARS-CoV-2 vaccines

Characteristics	18–59 yr group		≥60 yr group			
Groups	Fold-index <4	Fold–index ≥4	P value	Fold-index <4	Fold–index ≥4	P valu
Total number of cases	2	361		266		
Anti-spike IgG BAU/mL (2.5–97.5 percentile)	88.6–576.2		27.7–491.0			
Fold-index % (no.)*	7.5 (27/361)	92.5 (334/361)		11.7 (31/266)	88.3 (235/266)	
Anti-spike IgG BAU/mL						
Median (IQRs)	115.8 (88.6–167.8)	420.8 (369.9–480.6)	< 0.0001	63.9 (35.1–106.9)	346.0 (160.4–424.7)	< 0.0001
2.5–97.5 percentile	18.3–266.3	200.7–576.5		5.4–317.8	46.6–491.1	
Naïve immune cells (/mm ³)						
Lymphocytes, mean (95% CI)	1,130 (1,007–1,252)	1,578 (1,524–1,633)	< 0.0001	1,015 (888–1,143)	1,344 (1,291–1,397)	< 0.0001
CD4 cells, mean (95% CI)	631 (555–708)	942 (905–979)	< 0.0001	563 (494–631)	818 (777–858)	< 0.0001
CD8 cells, mean (95% CI)	414 (349–479)	532 (508–557)	0.0081	394 (310–478)	444 (420–468)	0.1744
B cells, mean (95% CI)	119 (72–166)	306 (289–323)	< 0.0001	74 (60–88)	248 (231–266)	< 0.0001
NK cells, mean (95% CI)	192 (151–233)	235 (220–251)	0.1241	281 (225–337)	286 (261–311)	0.8902

For the second vaccine dose. The reference ranges were defined as the 2.5–97.5
 percentile in the study.